A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 10 May 2016 Results published in the European Journal of Cancer
- 03 Sep 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 10 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.